期刊文献+

前列地尔联合辛伐他汀治疗颈动脉粥样硬化的临床观察 被引量:4

Effect of alprostadil combined with simvastatin on treatment of carotid atherosclerosis
下载PDF
导出
摘要 目的:探讨前列地尔联合辛伐他汀治疗颈动脉粥样硬化(CAS)的临床疗效。方法:将100例CAS患者随机分为治疗组和对照组。对照组给予辛伐他汀治疗,治疗组采用前列地尔联合辛伐他汀治疗,治疗2个月后检测颈动脉内膜中层厚度(IMT)、颈动脉斑块面积、颈总动脉的血流速度及颈总动脉内径的变化。结果:治疗组颈动脉IMT变薄、颈动脉斑块面积缩小,颈总动脉内径增宽、颈总动脉血流速度降低,与对照组比较有显著性差异(P<0.05)。结论:前列地尔联合辛伐他汀治疗CAS,能延缓、逆转CAS进展,增强斑块的稳定性,值得临床推广应用。 Objective:To investigate the effect of alprostadil combined with lipitor on treatment of carotid atherosclerosis(CAS).Methods:A total of 100 cases with CAS were randomly divided into treatment group and control group.The patients in control group were treated by simvastatin,and the patients in treatment group by alprostadil combined with simvastatin.After 2 months of continuous therapy the carotid intima-media thickness(IMT),area of carotid artery plaque,blood flow velocity of carotid artery and carotid artery diameter were detected.Results:After treatment the IMT was thinner and the area of carotid artery plaque was reduced in the treatment group compared with the control group,and there was significant difference(P0.05).The carotid artery diameter was broadened,and blood flow velocity of carotid artery was reduced in the treatment group,with significant difference comparing with control group(P0.05).Conclusions:The alprostadil combined with simvastatin can delay and reverse the progress of CAS,enhance the stability of atherosclerosis.It is worthy of clinical application.
出处 《海南医学院学报》 CAS 2011年第3期341-343,共3页 Journal of Hainan Medical University
基金 海南医学院科研基金资助学报项目(0020110071)~~
关键词 颈动脉粥样硬化 前列地尔 辛伐他汀 Carotid atherosclerosis Alprostadil Simvastatin
  • 相关文献

参考文献11

二级参考文献67

共引文献126

同被引文献26

  • 1高金明.原发性抗磷脂抗体综合征合并肺血栓栓塞[J].医师进修杂志,2005,28(2):7-9. 被引量:3
  • 2Hughes GRV. The anticardiolipin syndrome[J].Clinical and Experimental Rheumatology,1983.285.
  • 3Asherson RA,Cervera R,Piette JC. The antiphospholipid syndrome Ⅱ:autoimmune thrombosis[M].TetherIands Elsevier,2002.123-137.
  • 4Zhou H,Wolberg AS,Roubey RA. Characterizatio of monocyte tissue factor activity induced by IgG antiphosphospholipid antibodies and inhibition by dilazep[J].Blood,2004,(08):2352-2358.
  • 5Vega-Ostertag M,Harris EN,Pierangeli SS. Intracellular events in platet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin[J].Arthritis and Rheumatism,2004,(09):2911-2919.doi:10.1002/art.20434.
  • 6Safa O,Hensley K,Smirnov MD. Lipid oxidation enhances the function of activated protein C[J].Journal of Biological Chemistry,2001,(03):1829-1836.
  • 7Erkan D,Asherson RA,Espinosa G. Long term outcome of catastrophic antiphospholipid syndrome survivors[J].Annals of the Rheumatic Diseases,2003,(06):530-533.doi:10.1136/ard.62.6.530.
  • 8Finazzi G,Marchioli R,Brancaccio V. A randomized clinical trial of high-intensity warfarin vs.conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome(WAPS)[J].Journal of Thrombosis and Haemostasis,2005,(05):848-853.
  • 9Crowther MA,Ginberg JS,Julian J. A comparison of two intensites of warfarin for the prevention of recurrent thrombosis in patients with antiphospholipid antibody syndrome[J].New England Journal of Medicine,2003,(12):1133-1138.
  • 10Erkan D,Lockshin MD. New treatments for antiphospholipid syndrome[J].Rheumatic Diseases Clinics of North America,2006,(01):129-148.

引证文献4

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部